When CSL acquired flu vaccine business Seqirus from Novartis in 2015, Gordon Naylor was stunned by the lack of financial awareness among employees.

The former CSL chief financial officer and Seqirus boss was charged with merging and transforming two loss-making business units (Seqirus and bioCSL). His aim was for Seqirus to generate $1 billion in revenue within five years and for it to become profitable – something it achieved in 2018.